A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Phase 2

Terminated

Brief Summary: The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.

Detailed Description: The primary objective of the study is to collect long-term safety information on anetumab ravtansine and to enable patients, who received an anetumab ravtansine-containing treatment in any Bayer-sponsored anetumab ravtansine parent study, to continue the treatment. The secondary objective is to further investigate the efficacy of the drug.

Recruitment & Eligibility

Inclusion Criteria

Participants ongoing in an applicable Bayer-sponsored anetumab ravtansine parent study at the time of its planned study closure.
For on-treatment participants: participant is eligible to receive the next dose of study intervention per the parent study protocol.
For on-treatment participants: any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption. For applicable studies: should treatment be permanently interrupted in the parent study, participants may be enrolled in the follow-up portion of the rollover study.

Exclusion Criteria

For on-treatment participants: a positive serum pregnancy test.
For on-treatment participants: use of one or more of the prohibited medications listed in the respective parent study protocol.
Participants who are receiving standard-of-care agent(s) but not anetumab ravtansine in the parent study, and are able to receive standard-of-care agent outside of the clinical study.

Arm && Interventions

Group	Intervention	Description
Cancer patients	BAY94-9343 (Anetumab ravtansine)	Adult patients with solid cancer who received anetumab-ravtansine treatment in a completed Bayer study

Primary Outcome Measures

Name	Time	Method
Number of Participants With TEAEs, TESAEs and Drug-related TEAEs and TESAEs	Approximately 3 years (from first study treatment until safety follow-up)	Treatment emergent adverse events (TEAEs) were defined as AEs starting or worsening during the treatment period. The treatment period extended from the first date of study treatment in this study until the safety follow-up (30 days after the last administration of study treatment). TESAEs: Treatment emergent serious adverse events.

Secondary Outcome Measures

Name	Time	Method
Overall Survival	Approximately 3 years (from first study treatment until safety follow-up)	Overall survival (OS) defined as the time from first treatment in this study until death from any cause. Data on survival were collected by the site. Time frame was reduced due to early termination of the study. Table reports Kaplan-Meier median with Brookmeyer-Crowley confidence intervals. Number (%) of participants with event: 5 (55.6%) and Number (%) of participants censored: 4 (44.4%).

Locations (7): Sarah Cannon Cancer Center
🇺🇸
Nashville, Tennessee, United States
ASST Grande Ospedale Metropolitano Niguarda
🇮🇹
Milano, Lombardia, Italy
Mary Crowley Medical Research Center
🇺🇸
Dallas, Texas, United States
University of Chicago
🇺🇸
Chicago, Illinois, United States
Samodzielny Publiczny Wojewodzki Szpital Zespolony
🇵🇱
Szczecin-Zdunowo, Poland
National Cancer Institute - Maryland
🇺🇸
Bethesda, Maryland, United States
Hôpital de la Timone - Marseille
🇫🇷
Marseille, France